S-1/A: Mustang Bio Files Amendment No. 1 to Form S-1 Registration Statement for Resale of Common Stock

Mustang Bio is registering the resale of up to 2,743,530 shares of common stock by selling stockholders upon exercise of warrants.

Summary

• Mustang Bio, a clinical-stage biopharmaceutical company, filed an amendment to its Form S-1 registration statement.
• The filing relates to the resale of up to 2,743,530 shares of common stock by selling stockholders.
• These shares are issuable upon the exercise of certain warrants held by the selling stockholders.
• The company will not receive any proceeds from the sale of these shares.
• The company is focused on developing cell and gene therapies for hematologic cancers, solid tumors, and rare genetic diseases.
• Their pipeline includes CAR T therapies being developed in partnership with institutions like City of Hope, Fred Hutch, and Mayo Clinic.
• The company recently discontinued development of several gene therapy product candidates.
• Mustang Bio is facing financial challenges, including an accumulated deficit of $381.0 million as of December 31, 2023.
• There is substantial doubt regarding the company's ability to continue as a going concern.
• The company recently implemented a significant workforce reduction to reduce costs and preserve capital.
• The company is awaiting CFIUS review of the sale of its manufacturing facility to uBriGene.
• Mustang Bio received a notification from Nasdaq regarding non-compliance with continued listing requirements.
• Preliminary first quarter 2024 results indicate cash and cash equivalents of approximately $1.3 million and cash used in operating activities of $5.3 million.

Sentiment

Score: 3

Explanation: The document presents a mixed picture, with some positive clinical data but significant financial and operational challenges. The going concern warning and workforce reduction weigh heavily on the overall sentiment.

Positives

• MB-106 demonstrated a 100% overall response rate in indolent lymphoma patients in a Phase 1/2 clinical study.
• The FDA agreed with the proposed overall design of the pivotal trial for WM at the recommended dose of 1 x 107 CAR-T cells/kg and requested only minimal modifications to the study protocol.
• MB-109 received FDA clearance to proceed with a Phase 1 study.
• The company received RMAT designation from the FDA for MB-106 for the treatment of relapsed or refractory CD20 positive WM and FL.

Negatives

• The company has an accumulated deficit of $381.0 million as of December 31, 2023.
• There is substantial doubt regarding the company's ability to continue as a going concern.
• The company implemented a workforce reduction of approximately 81% to reduce costs.
• The company received a notification from Nasdaq regarding non-compliance with continued listing requirements.
• Due to limited resources, the company does not expect to initiate its pivotal Phase 2 single-arm clinical trial of MB-106 for the treatment of WM trial in 2024.

Risks

• The company's ability to continue as a going concern is uncertain.
• The company may need to raise additional funding, which may not be available on acceptable terms.
• Reliance on third parties for manufacturing increases the risk of insufficient quantities of product candidates.
• The trading price of the company's common stock is likely to continue to be highly volatile.
• A substantial number of shares of the company's common stock could be sold into the public market, which could depress the stock price.
• There can be no assurance that CFIUS will ultimately provide clearance with respect to the Transaction, or what mitigating measures may be required in order to obtain such clearance.

Future Outlook

The company expects to continue to incur significant operating losses for the foreseeable future and may never become profitable. The company intends to submit a Compliance Plan to Nasdaq on or before April 29, 2024. The company and uBriGene remain fully committed to obtaining clearance from CFIUS and completing the full transfer of the Facility to uBriGene.

Management Comments

• The document does not contain any direct quotes from management.

Industry Context

Mustang Bio is operating in the competitive field of cell and gene therapy, focusing on CAR T therapies. The company's partnerships with renowned research institutions are a common strategy in this sector to access cutting-edge technologies. The challenges faced by Mustang Bio, such as financial constraints and regulatory hurdles, are typical for companies in this industry, especially those in the clinical stage.

Comparison to Industry Standards

• The document does not contain any specific comparisons to industry standards.
• However, the company's focus on CAR T therapies places it in a similar space as companies like Juno Therapeutics (acquired by Celgene/Bristol Myers Squibb), Kite Pharma (acquired by Gilead), and Novartis, all of which have developed and commercialized CAR T cell therapies.
• The company's financial situation and recent workforce reduction suggest it is facing greater challenges than some of its larger, more established competitors.

Stakeholder Impact

• Shareholders face significant risk due to the company's financial instability and potential stock dilution.
• Employees have been impacted by the workforce reduction.
• The company's ability to develop and commercialize therapies for patients with unmet medical needs is at risk.
• The sale of the manufacturing facility may impact suppliers and other business partners.

Next Steps

• Submit a Compliance Plan to Nasdaq on or before April 29, 2024.
• Await the outcome of the CFIUS review of the sale of the manufacturing facility.
• Continue clinical development of MB-106 and MB-109, subject to available resources.
• Seek additional funding to support operations and clinical trials.

Key Dates

Keywords

Mustang Bio, common stock, resale, warrants, CAR T therapy, MB-106, MB-109, glioblastoma, CFIUS, manufacturing facility, workforce reduction, RMAT designation